Literature DB >> 4010871

Blood pressure and heart rate during treatment with nimodipine in patients with subarachnoid hemorrhage.

D Tettenborn, J Dycka, E Volberg, P Düdden.   

Abstract

Careful observation of blood pressure and heart rate in patients with subarachnoid hemorrhage during therapy with nimodipine showed that blood pressure decreases mainly in hypertensive patients during the first hours of therapy or when treatment is started immediately with 2 mg per hour instead of the recommended initial dose of 1 mg per hour. Predominantly mild or moderate reversible falls in blood pressure were reported as side effects in 21/421 patients (5%). Electrocardiographic abnormalities such as tachycardia, bradycardia, arrhythmia or extrasystoles were reported as side effects during treatment with nimodipine in 18 patients (4,3%). Since the association of ECG abnormalities with subarachnoid hemorrhage has been known for many years it is likely that these abnormalities are not typical side effects of nimodipine but belong to the natural course of the disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4010871     DOI: 10.1055/s-2008-1054109

Source DB:  PubMed          Journal:  Neurochirurgia (Stuttg)        ISSN: 0028-3819


  10 in total

1.  Severe myocardial depression following intravenous nimodipine for aneurysmal subarachnoid haemorrhage.

Authors:  Kandasamy Subramani; Murad Ghrew
Journal:  Intensive Care Med       Date:  2004-05-28       Impact factor: 17.440

2.  Plasma concentrations and haemodynamic effects of nimodipine in patients resuscitated after cardiac arrest.

Authors:  L P Huyghens; W A Buylaert; L Corne; M T Rosseel; M G Bogaert
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 3.  'Second generation' dihydropyridine calcium antagonists. Greater vascular selectivity and some unique applications.

Authors:  D D Freedman; D D Waters
Journal:  Drugs       Date:  1987-11       Impact factor: 9.546

4.  Survey of clinical experience with nimodipine in patients with subarachnoid hemorrhage.

Authors:  D Tettenborn; L Porto; T Ryman; V Strugo; G Taquoi; R Battye
Journal:  Neurosurg Rev       Date:  1987       Impact factor: 3.042

Review 5.  Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease.

Authors:  M S Langley; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

6.  Prevention of delayed cerebral vasospasm by continuous intrathecal infusion of glyceroltrinitrate and nimodipine in the rabbit model in vivo.

Authors:  Serge Marbacher; Volker Neuschmelting; Thilo Graupner; Stephan M Jakob; Javier Fandino
Journal:  Intensive Care Med       Date:  2008-01-24       Impact factor: 17.440

7.  Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial.

Authors:  J D Pickard; G D Murray; R Illingworth; M D Shaw; G M Teasdale; P M Foy; P R Humphrey; D A Lang; R Nelson; P Richards
Journal:  BMJ       Date:  1989-03-11

8.  A trial of the effect of nimodipine on outcome after head injury.

Authors:  I Bailey; A Bell; J Gray; R Gullan; O Heiskanan; P V Marks; H Marsh; D A Mendelow; G Murray; J Ohman
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

9.  Nimodipine: evidence for clinically significant gastrointestinal side-effects.

Authors:  E Hund; A Aschoff; V Tronnier; J Hampl; S Kunze
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

10.  Cerebral vasospasm pharmacological treatment: an update.

Authors:  Ioannis Siasios; Eftychia Z Kapsalaki; Kostas N Fountas
Journal:  Neurol Res Int       Date:  2013-01-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.